Cephalon, Inc. has signed a definitive merger agreement to acquire Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company, for $225 million cash. Gemin X stockholders could also receive as much as $300 million in cash payments based on certain regulatory and sales milestones. The agreement is subject to customary closing conditions including the necessary regulatory approvals. The merger is expected to close in 2Q11. Gemin X is developing a pipeline of targeted cancer thera...